We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here's Why You Should Invest in Masimo (MASI) Right Now
Read MoreHide Full Article
Masimo Corporation (MASI - Free Report) is currently one of the top-performing stocks in the MedTech space. An upbeat guidance for 2018 and a string of developments currently favor the stock.
Shares Up
Shares of Masimo have rallied 41.7% against the industry’s 7.4% decline in a year’s time. The current level is also lower than the S&P 500 index’s increase of 16.4%.
The stock currently has a Zacks Rank #2 (Buy).
What Makes Masimo an Attractive Pick?
Guidance Raised
Masimo recently saw a solid second quarter of 2018. Buoyed by the results, the company raised its 2018 earnings and revenue guidance.
Revenues are expected at $850 million, up from the previous guidance of $846 million. Notably, this reflects growth of 10.8% at constant currency. Product revenues are projected at $822 million, up from the previously projected $818 million. The company has retained the guidance for the Royalty and Other segment.
Adjusted earnings per share are expected at $2.90, up from the earlier estimated figure of $2.88.
Other Developments
Masimo has been lately witnessing a slew of developments.
Recently, the California-based MedTech company announced FDA clearance of RAS-45, an acoustic respiration sensor for Rainbow Acoustic Monitoring for infant and neonatal patients.
For the current quarter, the Zacks Consensus Estimate for earnings is pegged at 68 cents. The same for revenues stands at $206.3 million, reflecting year-over-year growth of 6.5%.
For the current year, the Zacks Consensus Estimate for earnings is pinned at $2.90, showing growth of 18.4% from the previous year. The same for revenues is pegged at $850.2 million, indicating a rise of 6.5% from the previous year.
Other Key Picks
Other top-ranked stocks in the broader medical space are athenahealth , Intuitive Surgical (ISRG - Free Report) and Veeva Systems (VEEV - Free Report) .
Intuitive Surgical’s expected long-term earnings growth rate is 14.7%. The stock has a Zacks Rank #1.
Veeva Systems’ long-term earnings growth rate is projected at 19.3%. The stock carries a Zacks Rank #1.
5 Companies Verge on Apple-Like Run
Did you miss Apple's 9X stock explosion after they launched their iPhone in 2007? Now 2018 looks to be a pivotal year to get in on another emerging technology expected to rock the market. Demand could soar from almost nothing to $42 billion by 2025.
Reports suggest it could save 10 million lives per decade which could in turn save $200 billion in U.S. healthcare costs. A bonus Zacks Special Report names this breakthrough and the 5 best stocks to exploit it. Like Apple in 2007, these companies are already strong and coiling for potential mega-gains.
Image: Bigstock
Here's Why You Should Invest in Masimo (MASI) Right Now
Masimo Corporation (MASI - Free Report) is currently one of the top-performing stocks in the MedTech space. An upbeat guidance for 2018 and a string of developments currently favor the stock.
Shares Up
Shares of Masimo have rallied 41.7% against the industry’s 7.4% decline in a year’s time. The current level is also lower than the S&P 500 index’s increase of 16.4%.
The stock currently has a Zacks Rank #2 (Buy).
What Makes Masimo an Attractive Pick?
Guidance Raised
Masimo recently saw a solid second quarter of 2018. Buoyed by the results, the company raised its 2018 earnings and revenue guidance.
Revenues are expected at $850 million, up from the previous guidance of $846 million. Notably, this reflects growth of 10.8% at constant currency. Product revenues are projected at $822 million, up from the previously projected $818 million. The company has retained the guidance for the Royalty and Other segment.
Adjusted earnings per share are expected at $2.90, up from the earlier estimated figure of $2.88.
Other Developments
Masimo has been lately witnessing a slew of developments.
Recently, the California-based MedTech company announced FDA clearance of RAS-45, an acoustic respiration sensor for Rainbow Acoustic Monitoring for infant and neonatal patients.
Last month, Masimo announced that its SET Measure-through Motion and Low Perfusion pulse oximetry can successfully identify children with Down Syndrome. (Read More: Masimo's SET Pulse Oximetry Detects Sleep Apnea in Children)
Which Way Are Estimates Treading?
For the current quarter, the Zacks Consensus Estimate for earnings is pegged at 68 cents. The same for revenues stands at $206.3 million, reflecting year-over-year growth of 6.5%.
Masimo Corporation Price and Consensus
Masimo Corporation Price and Consensus | Masimo Corporation Quote
For the current year, the Zacks Consensus Estimate for earnings is pinned at $2.90, showing growth of 18.4% from the previous year. The same for revenues is pegged at $850.2 million, indicating a rise of 6.5% from the previous year.
Other Key Picks
Other top-ranked stocks in the broader medical space are athenahealth , Intuitive Surgical (ISRG - Free Report) and Veeva Systems (VEEV - Free Report) .
athenahealth has a long-term expected earnings growth rate of 17.6%. The stock sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Intuitive Surgical’s expected long-term earnings growth rate is 14.7%. The stock has a Zacks Rank #1.
Veeva Systems’ long-term earnings growth rate is projected at 19.3%. The stock carries a Zacks Rank #1.
5 Companies Verge on Apple-Like Run
Did you miss Apple's 9X stock explosion after they launched their iPhone in 2007? Now 2018 looks to be a pivotal year to get in on another emerging technology expected to rock the market. Demand could soar from almost nothing to $42 billion by 2025.
Reports suggest it could save 10 million lives per decade which could in turn save $200 billion in U.S. healthcare costs. A bonus Zacks Special Report names this breakthrough and the 5 best stocks to exploit it. Like Apple in 2007, these companies are already strong and coiling for potential mega-gains.
Click to see them right now >>